Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Profile of novel topoisomerase II inhibitor, ER-37328, from Eisai

Dec. 11, 1997

Protein farnesyltransferase inhibitors focus of research at Merck & Co.

Dec. 11, 1997

ImClone Systems' C225 enters phase II for metastatic renal cell carcinoma

Dec. 11, 1997

SDZ-PSC-833 increases oral bioavailability of paclitaxel

Dec. 10, 1997

Oncologic Drugs Advisory Committee meets next week

Dec. 10, 1997

Preclinical toxicity profile of ISIS-2503

Dec. 9, 1997

SunPharm's anticancer drug completes phase I

Dec. 8, 1997

IntraBiotics signs manufacturing and supply agreement for IB-367

Dec. 8, 1997

Zeneca selects EGFR-TK inhibitor for clinical evaluation

Dec. 8, 1997

Oncaspar approved in Canada

Dec. 5, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...